This phase II MATCH treatment trial identifies the effects of dasatinib in patients whose cancer has a genetic change called DDR2 mutation. Dasatinib may block proteins called tyrosine kinases, which may be needed for cancer cell growth. Researchers hope to learn if dasatinib will shrink this type of cancer or stop its growth.

NCT04439305

Conditions

1. Advanced Lymphoma
2. Advanced Malignant Solid Neoplasm
3. Hematopoietic and Lymphoid Cell Neoplasm
4. Refractory Lymphoma
5. Refractory Malignant Solid Neoplasm
6. Refractory Plasma Cell Myeloma

Interventions

1. Drug: Dasatinib

MeSH:Lymphoma Neoplasms Multiple Myeloma Neoplasms, Plasma Cell

HPO:Lymphoma Multiple myeloma Neoplasm

PFS will be estimated using the Kaplan-Meier method.. Inclusion Criteria: - Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol - Patients must have one of the following missense mutations in DDR2: S768R, I638F, L239R - Patients must have an electrocardiogram (ECG) within 8 weeks prior to treatment assignment and must have no clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g. --- S768R ---

Antacids taken 2 hours before or after dasatinib administration can be used in place of H2-antagonists or proton pump inhibitors if some acid-reducing therapy is needed Inclusion Criteria: - Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol - Patients must have one of the following missense mutations in DDR2: S768R, I638F, L239R - Patients must have an electrocardiogram (ECG) within 8 weeks prior to treatment assignment and must have no clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g. --- S768R ---